微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: PBMs agree to display TrumpRx drug prices
RSS 官方收录 · 可信分层展示
关键摘要
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.…
- patent fight over Entresto.
- My son built a structurally sound bridge yesterday out of latticed twi…
- It was a moment of great pride.
摘要引擎：抽取
正文提要
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K. patent fight over Entresto.
My son built a structurally sound bridge yesterday out of latticed twigs; it supported my weight and also his. It was a moment of great pride. Hire him, he’s 8.
Bristol’s Zenbexus wins accelerated approval in multiple myeloma
The Food and Drug Administration yesterday approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.S. regulators using a more sensitive measure of remission.